中外医疗
中外醫療
중외의료
CHINA FOREIGN MEDICAL TREATMENT
2015年
22期
48-50
,共3页
石瑞平%郭树霞%陈荣华%范玮%秦娜%王艳梅
石瑞平%郭樹霞%陳榮華%範瑋%秦娜%王豔梅
석서평%곽수하%진영화%범위%진나%왕염매
三氧化二砷%化疗%难治性复发性恶性血液病%临床效果
三氧化二砷%化療%難治性複髮性噁性血液病%臨床效果
삼양화이신%화료%난치성복발성악성혈액병%림상효과
Arsenic trioxide%Chemotherapy%Refractory and recurrent hematologic malignancies%Clinical effect
目的:探究三氧化二砷联合化疗治疗难治性及复发性恶性血液病的临床效果,为患者的治疗寻找最有效的方式。方法将2012年3月-2015年3月该院收治的80例难治性及复发性恶性血液病患者为研究对象,按照治疗方式的不同分为对照组与观察组各40例,对照组给予单纯化疗,观察组在此基础上给予三氧化二砷联合治疗,比较两组的治疗效果与不良反应。结果观察组患者治疗后的总有效率(87.5%)显著高于对照组(65.0%)(P<0.05),且毒副反应的发生率(27.5%)显著低于对照组(65.0%)(P<0.05)。结论三氧化二砷联合化疗治疗难治性及复发性恶性血液病临床效果显著,且治疗过程中出现的毒副反应少,是一种值得借鉴的临床治疗方式。
目的:探究三氧化二砷聯閤化療治療難治性及複髮性噁性血液病的臨床效果,為患者的治療尋找最有效的方式。方法將2012年3月-2015年3月該院收治的80例難治性及複髮性噁性血液病患者為研究對象,按照治療方式的不同分為對照組與觀察組各40例,對照組給予單純化療,觀察組在此基礎上給予三氧化二砷聯閤治療,比較兩組的治療效果與不良反應。結果觀察組患者治療後的總有效率(87.5%)顯著高于對照組(65.0%)(P<0.05),且毒副反應的髮生率(27.5%)顯著低于對照組(65.0%)(P<0.05)。結論三氧化二砷聯閤化療治療難治性及複髮性噁性血液病臨床效果顯著,且治療過程中齣現的毒副反應少,是一種值得藉鑒的臨床治療方式。
목적:탐구삼양화이신연합화료치료난치성급복발성악성혈액병적림상효과,위환자적치료심조최유효적방식。방법장2012년3월-2015년3월해원수치적80례난치성급복발성악성혈액병환자위연구대상,안조치료방식적불동분위대조조여관찰조각40례,대조조급여단순화료,관찰조재차기출상급여삼양화이신연합치료,비교량조적치료효과여불량반응。결과관찰조환자치료후적총유효솔(87.5%)현저고우대조조(65.0%)(P<0.05),차독부반응적발생솔(27.5%)현저저우대조조(65.0%)(P<0.05)。결론삼양화이신연합화료치료난치성급복발성악성혈액병림상효과현저,차치료과정중출현적독부반응소,시일충치득차감적림상치료방식。
Objective To explore the clinical effect of arsenic trioxide combined with chemotherapy for treatment of refractory and recurrent hematologic malignancies so as to optimize its treatment. Methods 80 patients with refractory and recurrent hematologic malignancies admitted in our hospital from March 2012 and March 2015 were selected as the research object and divided into control group and observation group according to therapeutic schemes. Single chemotherapy was performed in the control group while arsenic trioxide combined with chemotherapy was used in the observation group. The clinical effects and adverse reactions were compared between the two groups. Results The total effective rate was significantly higher and the incidence of adverse reac-tions significantly lower, in the observation group than in the control group, 87.5% vs 65.0% and 27.5% vs 65.0%, respectively, and the differences were statistically significant (P<0.05). Conclusion The clinical effect of arsenic trioxide combined with chemotherapy for treatment of refractory and recurrent hematologic malignancies is remarkable, which shows less adverse reaction. Therefore it is worthy of application.